Navigation Links
Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
Date:10/16/2007

Up to One Quarter of Managed Care Organizations Fail to Cover Agents with Proven Benefit for Cancer Patients, According to a New Report from Decision

Resources

WALTHAM, Mass., Oct. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that oncologists want to see significant improvement in overall survival before adopting targeted polypharmacy in first-line settings. According to the new Physician & Payer Forum report entitled Premium-Priced Targeted Agents in Oncology: Clinician and Payer Attitudes to Polypharmacy, surveyed oncologists were asked what the minimum benefit is that would persuade them to add ImClone/Bristol-Myers Squibb/Merck KGaA's Erbitux to Genentech/Roche's Avastin and chemotherapy for first-line treatment of advanced non-small-cell lung cancer (NSCLC).

In this first-line treatment scenario, the largest group of oncologists (41 percent) would require a significant improvement in overall survival in order to add Erbitux to Avastin and chemotherapy. On average, oncologists require 24 percent improvement in median survival, which would represent close to three months' additional survival, a very difficult requirement to meet in advanced NSCLC. Only 37 percent of oncologists expect Erbitux/Avastin to increase median survival of NSCLC patients.

The report also finds that up to one quarter of managed care organizations (MCOs) fail to cover both agents where two similar targeted agents are available. Marketers of Tykerb, Nexavar, Sutent, and Sprycel need to address the fact that some MCOs appear to perceive Herceptin/Tykerb, Nexavar/Sutent, and Gleevec/Sprycel as interchangeable, "me too" agents.

"Evidence demonstrates that patients who have failed Herceptin in the metastatic setting should switch to Tykerb, patients who have failed Gleevec should switch to Sprycel, and, according to National Cancer Institute guidelines, patients who fail Sutent could benefit from Nexavar," said Mary Fletcher-Louis, analyst at Decision Resources. "To have only one from each of these couplets on formulary leaves important clinical scenarios uncovered."

Premium-Priced Targeted Agents in Oncology: Clinician and Payer Attitudes to Polypharmacy is based on a U.S. survey of 100 oncologists and 20 managed care pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical and economic factors in the management of premium-priced targeted agents in oncology.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high-volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Emerging technology companies receive significant funding
2. Genzyme acquistion of Bone Care approved, significant impact forecast
3. Chicago-Milwaukee "mega-metro" infrastructure improvements are critical
4. Manufacturing group says efforts led to big improvements
5. Part 6 Project Performance Get on the path to continuous improvement
6. Part 5 Project Performance Get on the path to continuous improvement
7. Part 4 Project Performance Get on the path to continuous improvement
8. Part 3 Project performance Get on the path to continuous improvement
9. Part 2 Project performance Get on the path to continuous improvement
10. Part 1 Project performance Get on the path to continuous improvement
11. Finding a Yardstick For Local Biotech Improvement and Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
Breaking Biology Technology:
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):